Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02 2021 - 4:30PM
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity
inducement grants to five new employees consisting of 20,440
restricted stock units. The Compensation Committee of the Board of
Directors approved the grants with an effective date of July 1,
2021. The restricted stock units were granted as inducements
material to the employees entering into employment with the Company
in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25% of the
shares vesting on each annual anniversary of the applicable vesting
commencement date, subject to the new employee’s continued service
relationship with the Company.
The restricted stock units are subject to the terms and
conditions of the Company's 2013 Equity Incentive Plan and a
restricted stock unit agreement covering the grant.
About Flexion TherapeuticsFlexion
Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company
focused on the development and commercialization of novel, local
therapies for the treatment of patients with musculoskeletal
conditions, beginning with osteoarthritis, the most common form of
arthritis. The company's core values are focus, ingenuity,
tenacity, transparency and fun. Please
visit flexiontherapeutics.com.
Contact:Scott YoungVice President, Corporate
Communications & Investor RelationsFlexion Therapeutics, Inc.T:
781-305-7194syoung@flexiontherapeutics.com
Flexion Therapeutics (NASDAQ:FLXN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Flexion Therapeutics (NASDAQ:FLXN)
Historical Stock Chart
From Sep 2023 to Sep 2024